Pain News and Research

Latest Pain News and Research

$Golden Jubilee National Hospital first to use revolutionary technology in rib fracture surgery$

Golden Jubilee National Hospital first to use revolutionary technology in rib fracture surgery

The Golden Jubilee National Hospital recently became the first hospital in Scotland to use a revolutionary new technology on a patient suffering from a severe rib fracture.

11 Dec 2014

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

10 Dec 2014

Variations in ERAP1 enzyme could lead to Ankylosing Spondylitis

Scientists at the University of Southampton have discovered variations in an enzyme belonging to the immune system that leaves individuals susceptible to Ankylosing Spondylitis.

10 Dec 2014

Report supports potential of focused ultrasound to treat certain OCD patients

A recently published report in the Journal of Molecular Psychiatry supports the potential of focused ultrasound to treat certain patients with obsessive-compulsive disorder (OCD).

10 Dec 2014

Research highlights potential of computers to enhance quality of care, medical outcomes

A computer system was more effective than doctors at collecting information about patient symptoms, producing reports that were more complete, organized and useful than narratives generated by physicians during office visits, according to a Cedars-Sinai study.

10 Dec 2014

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

Cannabis Science, CFA partner to improve health-related education infrastructure in Africa

Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its President & CEO, Mr. Raymond C. Dabney, along with CBIS's Senior Scientific Advisor, Dr. Roscoe M. Moore, Jr., have initiated a partnership between CBIS and the Constituency for Africa to help improve the healthcare and health-related education infrastructure in Africa.

9 Dec 2014

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles.

9 Dec 2014

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.

9 Dec 2014

Opioid tramadol can increase hospitalization risk for hypoglycemia

The opioid pain-reliever tramadol appears to be associated with an increased risk of hospitalization for hypoglycemia, a potentially fatal condition caused by low blood sugar, according to a report published online by JAMA Internal Medicine.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Nine in 10 primary care physicians say that prescription drug abuse is a moderate or big problem in their communities and nearly half say they are less likely to prescribe opioids to treat pain compared to a year ago, new Johns Hopkins Bloomberg School of Public Health research suggests.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

PRM-151 compound shows positive results for treating advanced myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

8 Dec 2014

Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine - better known as the anti-depressant Prozac - could hold the key to preventing PMS symptoms, an international team of researchers has found.

8 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program.

8 Dec 2014

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82).

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Study indicates major added benefit of propranolol in some children with haemangioma

The Institute for Quality and Efficiency in Health Care (IQWiG)investigated in a dossier assessment whether propranolol offers an added benefit in comparison with the appropriate comparator therapy in infants with proliferating infantile haemangioma (sometimes called "strawberry mark").

7 Dec 2014

Pain News and Research

Latest Pain News and Research

Golden Jubilee National Hospital first to use revolutionary technology in rib fracture surgery

Mylan announces U.S. launch of Celecoxib Capsules

Variations in ERAP1 enzyme could lead to Ankylosing Spondylitis

Report supports potential of focused ultrasound to treat certain OCD patients

Research highlights potential of computers to enhance quality of care, medical outcomes

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Cannabis Science, CFA partner to improve health-related education infrastructure in Africa

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Opioid tramadol can increase hospitalization risk for hypoglycemia

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

PRM-151 compound shows positive results for treating advanced myelofibrosis

Low doses of fluoxetine could hold key to preventing PMS symptoms

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Study indicates major added benefit of propranolol in some children with haemangioma

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Pain News and Research

Latest Pain News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in